Clinical study of ESHAP regimen for relapsed or refractory aggressive non-Hodgkin lymphoma
- VernacularTitle:ESHAP方案治疗复发或难治性侵袭性非霍奇金淋巴瘤
- Author:
Sheng LUO
;
Xu-Dong HU
;
Zhi-Jian SHEN
;
Jun-Li ZHANG
;
Lan SUN
;
Yi CHEN
;
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Antineoplastie combined chemotherapy protocols;
Therapy
- From:
Cancer Research and Clinic
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of ESHAP regimen,as a salvage regimen, in treating patients with relapsed or refractory aggressive NHL.Methods 38 patients with relapsed or refrac- tory aggressive NHL were selected to be treated by ESHAP regimen.Results The 38 patients received ES- HAP regimen with a range of 2～6 cycles. The total RR was 55.3 % with complete response(CR)rate of 26.3 %.The major toxicity was myelosuppression with infection,which was tolerable.Conclusion ESHAP regimen is one of safe and effective salvage regimens for the patients with relapsed or refractory aggressive NHL.
